Rhythm Pharmaceuticals, Inc. (RYTM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RYTM SEC filings page.
Rhythm Pharmaceuticals, Inc. (RYTM) reported $189.8M in revenue for fiscal year 2025, up 45.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue scale is improving, but external capital still finances a development-stage cost base and persistent operating cash use.
From FY2024 to FY2025, revenue expanded while operating margin improved from-204.0% to-101.2% , showing that additional gross profit and lower research spending absorbed part of the cost base. Yet operating cash flow remained near-$116M and free cash flow near-$117M in FY2025, so the accounting improvement has not translated into cash generation.
The 89.7% gross margin held steady, so FY2025’s narrower operating loss was not a gross-margin story. Research and development fell to
The balance sheet became less debt-heavy than FY2024: debt-to-equity fell from 5.0x to 0.7x. Financing cash flow was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Rhythm Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Rhythm Pharmaceuticals, Inc. held $392.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $115.7M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Rhythm Pharmaceuticals, Inc. scores 64/100 among other emerging companies.
Rhythm Pharmaceuticals, Inc. had 68M shares outstanding at the end of fiscal year 2025, against 63M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Rhythm Pharmaceuticals, Inc. scores 55/100 among other emerging companies.
Rhythm Pharmaceuticals, Inc. spent $167.3M on research and development in fiscal year 2025, which was 43.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Rhythm Pharmaceuticals, Inc. scores 74/100 among other emerging companies.
Rhythm Pharmaceuticals, Inc. reported revenue of $189.8M in fiscal year 2025, against $130.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Rhythm Pharmaceuticals, Inc. scores 81/100 among other emerging companies.
Rhythm Pharmaceuticals, Inc.'s operations used $115.7M of cash in fiscal year 2025, against $113.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Rhythm Pharmaceuticals, Inc. scores 54/100 among other emerging companies.
Rhythm Pharmaceuticals, Inc.'s cash, cash equivalents and investments came to $392.2M at the end of fiscal year 2025, against $341.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Rhythm Pharmaceuticals, Inc. scores 62/100 among other emerging companies.
Rhythm Pharmaceuticals, Inc. scores 7.28, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.4B) relative to total liabilities ($341.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Rhythm Pharmaceuticals, Inc. passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Rhythm Pharmaceuticals, Inc. reported a net loss of $197K while operations used $115.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Rhythm Pharmaceuticals, Inc. reported an operating loss of $192.0M against $20.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Rhythm Pharmaceuticals, Inc. generated $71.3M in revenue in Q2 2026. This represents an increase of 46.9% from the same quarter a year earlier. Against the prior quarter it is up 18.5%.
Rhythm Pharmaceuticals, Inc. reported -$49.3M in net income in Q2 2026. This represents a decrease of 5.7% from the same quarter a year earlier. Against the prior quarter it is up 11.4%.
Rhythm Pharmaceuticals, Inc. earned -$0.73 per diluted share (EPS) in Q2 2026. This represents an increase of 2.7% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.
Not reported for Q2 2026.
Cash & Balance Sheet
Rhythm Pharmaceuticals, Inc. held $65.6M in cash against $93.4M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Rhythm Pharmaceuticals, Inc.'s gross margin was 87.5% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.6 percentage points.
Rhythm Pharmaceuticals, Inc.'s operating margin was -68.1% in Q2 2026, reflecting core business profitability. This is up 25.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 19.0 percentage points.
Rhythm Pharmaceuticals, Inc.'s net profit margin was -69.2% in Q2 2026, showing the share of revenue converted to profit. This is up 27.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 23.4 percentage points.
Rhythm Pharmaceuticals, Inc.'s ROE was -47.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 2.6 percentage points.
Capital Allocation
Rhythm Pharmaceuticals, Inc. invested $43.4M in research and development in Q2 2026. This represents an increase of 2.6% from the same quarter a year earlier. Against the prior quarter it is up 4.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
RYTM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.3M+46.9% | $60.1M+83.8% | $57.3M+36.9% | $51.3M+54.3% | $48.5M+66.8% | $32.7M+25.9% | $41.8M+72.6% | $33.3M+47.8% |
| Cost of Revenue | $8.9M+61.1% | $7.2M+96.2% | $4.8M+26.8% | $5.5M+43.7% | $5.5M+88.1% | $3.6M+30.0% | $3.8M+17.1% | $3.8M+58.7% |
| Gross Profit | $62.3M+45.1% | $53.0M+82.3% | $52.5M+37.9% | $45.8M+55.7% | $43.0M+64.4% | $29.1M+25.5% | $38.0M+81.2% | $29.4M+46.4% |
| R&D Expenses | $43.4M+2.6% | $41.7M+12.9% | $42.0M+2.1% | $46.0M+21.3% | $42.3M+40.1% | $37.0M-71.3% | $41.2M+37.7% | $37.9M+13.0% |
| SG&A Expenses | $67.4M+46.8% | $63.6M+62.7% | $57.5M+50.8% | $52.4M+48.2% | $45.9M+26.2% | $39.1M+13.7% | $38.1M+17.8% | $35.4M+16.1% |
| Operating Income | -$48.6M-7.2% | -$52.4M-11.4% | -$47.1M-14.1% | -$52.7M-20.0% | -$45.3M-11.9% | -$47.0M+66.4% | -$41.3M0.0% | -$43.9M+0.2% |
| Interest Expense | $4.5M-22.0% | $4.6M-15.3% | $4.6M-23.1% | $4.7M-9.5% | $5.8M+26.4% | $5.4M+13.8% | $6.0M+37.1% | $5.2M+66.5% |
| Income Tax | $444K+31.8% | $545K+581.3% | -$31K+65.2% | $111K+132.3% | $337K-29.6% | $80K-73.3% | -$89K | -$344K-193.5% |
| Net Income | -$49.3M-5.7% | -$55.6M-12.4% | $148.8M-31.4% | -$52.9M-21.2% | -$46.6M-44.5% | -$49.5M+65.0% | $217.0M+51.9% | -$43.6M+1.2% |
| EPS (Basic) | -$0.73+2.7% | -$0.83-2.5% | -$0.73-1.4% | -$0.82-12.3% | -$0.75-36.4% | -$0.81+65.5% | -$0.72-2.9% | -$0.73+3.9% |
| EPS (Diluted) | -$0.73+2.7% | -$0.83-2.5% | -$0.73-1.4% | -$0.82-12.3% | -$0.75-36.4% | -$0.81+65.5% | -$0.72-2.9% | -$0.73+3.9% |
| Diluted Shares (Avg) | 69M+7.7% | 68M+7.8% | N/A | 66M+8.2% | 64M+4.4% | 63M+4.8% | N/A | 61M+5.8% |
Not reported in any period shown, so not listed: EBITDA.
RYTM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $437.3M+17.3% | $442.3M+14.4% | $480.2M+22.4% | $506.9M+39.4% | $372.7M-2.4% | $386.7M+49.5% | $392.3M+17.9% | $363.6M+2.6% |
| Current Assets | $426.6M+18.3% | $430.1M+16.5% | $466.9M+24.8% | $494.8M+45.4% | $360.7M+0.9% | $369.3M+56.6% | $374.2M+21.4% | $340.3M+3.4% |
| Cash & Equivalents | $65.6M-51.6% | $62.1M-41.4% | $54.3M-39.1% | $52.1M+9.6% | $135.6M-16.1% | $106.1M+98.6% | $89.1M+48.4% | $47.5M-26.4% |
| Short-Term Investments | $265.3M+70.7% | $278.5M+33.6% | $334.6M+44.6% | $364.0M+45.1% | $155.4M-1.3% | $208.4M+41.0% | $231.4M+7.3% | $250.9M+6.9% |
| Inventory | $30.5M+61.7% | $28.7M+48.3% | $25.8M+37.4% | $22.1M+59.1% | $18.9M+57.3% | $19.3M+127.1% | $18.7M+117.3% | $13.9M+79.0% |
| Accounts Receivable | $40.4M+54.7% | $34.2M+91.8% | $26.1M+40.9% | $33.0M+71.1% | $26.1M+48.4% | $17.8M+21.3% | $18.5M+24.5% | $19.3M+32.8% |
| Long-Term Investments | $2.3M+3.1% | $2.5M-64.8% | $3.3M-55.1% | $2.5M-79.4% | $2.2M-82.6% | $7.1M-48.2% | $7.3M-51.2% | $12.0M-20.0% |
| Total Liabilities | $334.3M-13.1% | $319.4M-13.1% | $341.1M-7.9% | $358.1M+1.6% | $384.6M+12.3% | $367.7M+86.6% | $370.5M+127.3% | $352.4M+124.8% |
| Current Liabilities | $123.6M-4.5% | $103.2M-7.7% | $105.9M-8.3% | $104.3M+6.8% | $129.5M+136.6% | $111.8M+106.5% | $115.5M+109.3% | $97.6M+94.6% |
| Non-Current Liabilities | $210.7M-17.4% | $216.2M-15.5% | $235.2M-7.8% | $253.8M-0.4% | $255.2M-11.3% | $255.9M+79.1% | $255.0M+136.6% | $254.8M+139.0% |
| Long-Term Debt | $93.4M-11.9% | $98.3M-8.9% | $100.9M-6.8% | $103.4M | $106.0M | $107.9M | $108.3M+2.0% | N/A |
| Total Equity | $103.0M+964.8% | $122.9M+548.7% | $139.1M+540.0% | $148.8M+1226.9% | -$11.9M-130.3% | $18.9M-69.2% | $21.7M-87.2% | $11.2M-94.3% |
| Retained Earnings | -$1.5B-16.4% | -$1.4B-16.8% | -$1.4B-17.0% | -$1.3B-17.3% | -$1.3B-17.1% | -$1.2B-16.3% | -$1.2B-29.1% | -$1.1B-30.3% |
Not reported in any period shown, so not listed: Goodwill.
RYTM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.2M+60.7% | -$44.2M-9.5% | -$25.4M-34.7% | -$26.6M-5.6% | -$23.3M+19.8% | -$40.4M+1.0% | -$18.8M+35.9% | -$25.2M+13.8% |
| Stock-Based Compensation | N/A | $23.1M+79.6% | N/A | N/A | N/A | $12.9M+65.6% | N/A | N/A |
| Investing Cash Flow | $14.0M-74.1% | $57.1M+129.9% | $30.3M+43.4% | -$246.3M-171.3% | $54.0M+731.1% | $24.8M-17.4% | $21.2M-6.6% | -$90.8M+4.4% |
| Financing Cash Flow | -$1.2M-31.0% | -$5.4M-116.6% | -$2.9M-107.7% | $189.3M+7496.3% | -$889K-100.6% | $32.5M+665.9% | $38.3M+1481.8% | $2.5M-96.6% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
RYTM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.5%-1.1pp | 88.1%-0.8pp | 91.6%+0.7pp | 89.3%+0.8pp | 88.6%-1.3pp | 88.8%-0.3pp | 91.0%+4.3pp | 88.5%-0.8pp |
| Operating Margin | -68.1%+25.2pp | -87.1% | -82.2%+16.4pp | -102.6% | -93.4% | -143.7% | -98.6% | -132.0% |
| Net Margin | -69.2%+27.0pp | -92.6% | 260.0% | -103.1% | -96.1% | -151.3% | 518.8% | -131.3% |
| Return on Equity | -47.9% | -45.3%+216.0pp | 107.0%-891.7pp | -35.5%+353.6pp | N/A | -261.2%-31.7pp | 998.7%+914.6pp | -389.1%-366.8pp |
| Return on Assets | -11.3%+1.2pp | -12.6%+0.2pp | 31.0%-24.3pp | -10.4%+1.6pp | -12.5%-4.1pp | -12.8%+41.9pp | 55.3%+12.4pp | -12.0%+0.5pp |
| Current Ratio | 3.45+0.7x | 4.17+0.9x | 4.41+1.2x | 4.75+1.3x | 2.79-3.7x | 3.30-1.1x | 3.24-2.3x | 3.49-3.1x |
| Debt-to-Equity | 0.91 | 0.80-4.9x | 0.73-4.3x | 0.69-30.7x | N/A | 5.70+2.5x | 4.98+4.4x | 31.42+30.6x |
| Asset Turnover | 0.160.0x | 0.14+0.1x | 0.120.0x | 0.100.0x | 0.13+0.1x | 0.080.0x | 0.110.0x | 0.090.0x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. RYTM | FY2025 | $189.8M | -$197K | -0.1% | $6.4B | 65/100 |
| Legend Biotech Corporation LEGN | FY2025 | $1.0B | -$296.8M | -28.8% | $3.6B | 41/100 |
| Cytokinetics Inc. CYTK | FY2025 | $88.0M | -$785.0M | N/A | $9.1B | 60/100 |
| Axsome Therapeutics, Inc AXSM | FY2025 | $638.5M | -$183.2M | -28.7% | $9.4B | 37/100 |
| Nuvalent, Inc. NUVL | FY2025 | N/A | -$425.4M | N/A | $9.8B | — |
Where Rhythm Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Rhythm Pharmaceuticals, Inc.'s annual revenue?
Rhythm Pharmaceuticals, Inc. (RYTM) reported $189.8M in total revenue for fiscal year 2025. This represents a 45.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Rhythm Pharmaceuticals, Inc.'s revenue growing?
Rhythm Pharmaceuticals, Inc. (RYTM) revenue grew by 45.8% year-over-year, from $130.1M to $189.8M in fiscal year 2025.
Is Rhythm Pharmaceuticals, Inc. profitable?
No, Rhythm Pharmaceuticals, Inc. (RYTM) reported a net income of -$197K in fiscal year 2025, with a net profit margin of -0.1%.
What is Rhythm Pharmaceuticals, Inc.'s EBITDA?
Rhythm Pharmaceuticals, Inc. (RYTM) had EBITDA of -$191.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Rhythm Pharmaceuticals, Inc. have?
As of fiscal year 2025, Rhythm Pharmaceuticals, Inc. (RYTM) had $54.3M in cash and equivalents against $100.9M in long-term debt.
What is Rhythm Pharmaceuticals, Inc.'s gross margin?
Rhythm Pharmaceuticals, Inc. (RYTM) had a gross margin of 89.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Rhythm Pharmaceuticals, Inc.'s net profit margin?
Rhythm Pharmaceuticals, Inc. (RYTM) had a net profit margin of -0.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Rhythm Pharmaceuticals, Inc.'s return on equity (ROE)?
Rhythm Pharmaceuticals, Inc. (RYTM) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rhythm Pharmaceuticals, Inc.'s free cash flow?
Rhythm Pharmaceuticals, Inc. (RYTM) recorded an outflow of $116.6M in free cash flow during fiscal year 2025. This represents a -2.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Rhythm Pharmaceuticals, Inc.'s operating cash flow?
Rhythm Pharmaceuticals, Inc. (RYTM) recorded an outflow of $115.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Rhythm Pharmaceuticals, Inc.'s total assets?
Rhythm Pharmaceuticals, Inc. (RYTM) had $480.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Rhythm Pharmaceuticals, Inc.'s capital expenditures?
Rhythm Pharmaceuticals, Inc. (RYTM) invested $953K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Rhythm Pharmaceuticals, Inc. spend on research and development?
Rhythm Pharmaceuticals, Inc. (RYTM) invested $167.3M in research and development during fiscal year 2025.
What is Rhythm Pharmaceuticals, Inc.'s current ratio?
Rhythm Pharmaceuticals, Inc. (RYTM) had a current ratio of 4.41 as of fiscal year 2025, which is generally considered healthy.
What is Rhythm Pharmaceuticals, Inc.'s debt-to-equity ratio?
Rhythm Pharmaceuticals, Inc. (RYTM) had a debt-to-equity ratio of 0.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rhythm Pharmaceuticals, Inc.'s return on assets (ROA)?
Rhythm Pharmaceuticals, Inc. (RYTM) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rhythm Pharmaceuticals, Inc.'s P/E ratio?
Rhythm Pharmaceuticals, Inc. (RYTM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $6.4B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Rhythm Pharmaceuticals, Inc.'s price-to-sales ratio?
Rhythm Pharmaceuticals, Inc. (RYTM) trades at 26.6x sales, its market capitalization divided by revenue of $239.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $6.4B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Rhythm Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Rhythm Pharmaceuticals, Inc. (RYTM) held $392.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $115.7M over that year. Dividing the one by the other, the reported balance equals about 41 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Rhythm Pharmaceuticals, Inc.'s Altman Z-Score?
Rhythm Pharmaceuticals, Inc. (RYTM) has an Altman Z-Score of 7.28, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Rhythm Pharmaceuticals, Inc.'s Piotroski F-Score?
Rhythm Pharmaceuticals, Inc. (RYTM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rhythm Pharmaceuticals, Inc.'s earnings high quality?
Rhythm Pharmaceuticals, Inc. (RYTM) reported a net loss of $197K while operations used $115.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Rhythm Pharmaceuticals, Inc. cover its interest payments?
Rhythm Pharmaceuticals, Inc. (RYTM) reported an operating loss of $192.0M against $20.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Rhythm Pharmaceuticals, Inc.?
Rhythm Pharmaceuticals, Inc. (RYTM) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.